Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1073-1083

  Guin, Sunny ^a   Ma, Qi ^a   Padhye, Snehal ^a   Zhou, Yong Qing ^b   Yao, Hang Ping ^c   Wang, Ming Hai ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Colon cancer cells; Drug delivery; Hypoxia; Immunoliposome; Monoclonal antibody; Receptor tyrosine kinase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBON DIOXIDE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ZT G4; NITROGEN; OXYGEN; PROTEIN RON; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HCC1937; CELL STRAIN HCT116; CELL STRAIN SW620; CELL VIABILITY; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG BINDING SITE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; HYPOXIC CELL; IC 50; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOSOMES; RECEPTOR PROTEIN-TYROSINE KINASES; TIME FACTORS;

EID: 79955555773     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1408-8     Document Type: Article

References (47)

1. RH Thomlinson LH Gray 1955 The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9 539 549 13304213 10.1038/bjc.1955.55 1:STN:280:DyaG28%2Fls1Gltg%3D%3D
2. GL Semenza 2010 Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 29 625 634 19946328 10.1038/onc.2009.441 1:CAS:528:DC%2BD1MXhsV2gt77N
3. AL Harris 2002 Hypoxia-a key regulatory factor in tumor growth Nat Rev Cancer 2 38 47 11902584 10.1038/nrc704 1:CAS:528:DC%2BD38XhvF2jtL4%3D (Pubitemid 37328806)
4. EB Rankin AJ Giaccia 2008 The role of hypoxia-inducible factors in tumorigenesis Cell Death Differ 15 678 685 18259193 10.1038/cdd.2008.21 1:CAS:528:DC%2BD1cXjtl2jur8%3D (Pubitemid 351405072)
5. MM Hickey MC Simon 2006 Regulation of angiogenesis by hypoxia and hypoxia-inducible factors Curr Top Dev Biol 76 217 257 17118268 10.1016/S0070-2153(06)76007-0 1:CAS:528:DC%2BD2sXmsFOms7g%3D (Pubitemid 44773777)
6. N Chaudary RP Hill 2007 Hypoxia and metastasis Clin Cancer Res 13 1947 1949 17404073 10.1158/1078-0432.CCR-06-2971 1:CAS:528:DC%2BD2sXjs12rsb0%3D (Pubitemid 46649858)
7. O Trédan CM Galmarini K Patel IF Tannock 2007 Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 1441 1454 17895480 10.1093/jnci/djm135
8. K Yokoi IJ Fidler 2004 Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine Clin Cancer Res 10 2299 2306 15073105 10.1158/1078-0432.CCR-03-0488 1:CAS:528:DC%2BD2cXivFSqsrk%3D (Pubitemid 38445687)
9. S Rockwell IT Dobrucki EY Kim ST Marrison VT Vu 2009 Hypoxia and radiation therapy: past history, ongoing research, and future promise Curr Mol Med 9 442 458 19519402 10.2174/156652409788167087 1:CAS:528:DC%2BD1MXmvVWqsrg%3D
10. C Ronsin F Muscatelli MG Mattei R Breathnach 1993 A novel putative receptor protein tyrosine kinase of the met family Oncogene 8 1195 1202 8386824 1:CAS:528:DyaK3sXks1ClsL4%3D (Pubitemid 23129841)
11. M-H Wang C Ronsin M-C Gesnel L Coupey A Skeel EJ Leonard R Breathnach 1994 Identification of the RON gene product as the receptor for the human macrophage stimulating protein Science 266 117 119 7939629 10.1126/science. 7939629 1:CAS:528:DyaK2cXmvFemtLo%3D (Pubitemid 24345331)
12. PK Wagh BE Peace SE Waltz 2008 Met-related receptor tyrosine kinase Ron in tumor growth and metastasis Adv Cancer Res 100 1 33 18620091 10.1016/S0065-230X(08)00001-8 1:CAS:528:DC%2BD1cXhtVajsrbJ (Pubitemid 351942429)
13. MH Wang W Lee YL Luo MT Weis HP Yao 2007 Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells J Pathol 213 402 411 17955509 10.1002/path.2245 1:CAS:528:DC%2BD1cXhvFKjug%3D%3D (Pubitemid 350206512)
14. RM Thomas K Toney C Fenoglio-Preiser MP Revelo-Penafiel SR Hingorani DA Tuveson SE Waltz AM Lowy 2007 The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression Cancer Res 67 6075 6082 17616662 10.1158/0008-5472.CAN-06-4128 1:CAS:528:DC%2BD2sXnsVyqsbw%3D (Pubitemid 47037486)
15. AL Welm JB Sneddon C Taylor DS Nuyten MJ van de Vijver BH Hasegawa JM Bishop 2007 The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans Proc Natl Acad Sci USA 104 7570 7575 17456594 10.1073/pnas.0702095104 1:CAS:528: DC%2BD2sXlslWqtL0%3D (Pubitemid 47185947)
16. MH Wang D Wang YQ Chen 2003 Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase Carcinogenesis 24 1291 1300 12807733 10.1093/carcin/bgg089 1:CAS:528: DC%2BD3sXmtFKktbc%3D (Pubitemid 37038819)
17. ER Camp W Liu F Fan A Yang R Somcio LM Ellis 2005 RON, a tyrosine kinase receptor involved in tumor progression and metastasis Ann Surg Oncol 12 273 281 15827676 10.1245/ASO.2005.08.013 (Pubitemid 40616491)
18. J Logan-Collins RM Thomas P Yu, et al. 2010 Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers Cancer Res 70 1130 1140 20103639 10.1158/0008-5472.CAN-09-0761 1:CAS:528:DC%2BC3cXht12rur8%3D
19. WY Lee HH Chen NH Chow WC Su PW Lin HR Guo 2005 Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients Clin Cancer Res 11 2222 2228 15788670 10.1158/1078-0432.CCR-04-1761 1:CAS:528:DC%2BD2MXisFajurk%3D (Pubitemid 40490180)
20. I Dussault SF Bellon 2009 From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer Anticancer Agents Med Chem 9 221 229 19199866 1:CAS:528:DC%2BD1MXjvVOmsLs%3D
21. JM O'Toole KE Rabenau K Burns, et al. 2006 Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member Cancer Res 66 9162 9170 16982759 10.1158/0008-5472.CAN-06-0283 (Pubitemid 44521136)
22. Y Zhang PJ Kaplan-Lefko, et al. 2008 Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo Cancer Res 68 6680 6687 18701492 10.1158/0008-5472.CAN-07-6782 1:CAS:528:DC%2BD1cXpslKms7s%3D
23. JG Christensen R Schreck J Burrows, et al. 2003 A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo Cancer Res 63 7345 7355 14612533 1:CAS:528:DC%2BD3sXovVGltL4%3D (Pubitemid 37413476)
24. Guin S, Yao HP, Wang MH (2010) RON Receptor Tyrosine Kinase as a Target for Delivery of Chemodrugs by Antibody Directed Pathway for Cancer Cell Cytotoxicity. Mol Pharm (in press)
25. RH Xu H Pelicano Y Zhou JS Carew L Feng KN Bhalla MJ Keating P Huang 2005 Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia Cancer Res 65 613 621 15695406 10.1158/0008-5472.CAN-04-4313 1:CAS:528: DC%2BD2MXns1Ojuw%3D%3D (Pubitemid 40911174)
26. M Milani AL Harris 2008 Targeting tumor hypoxia in breast cancer Eur J Cancer 44 2766 2773 18990559 10.1016/j.ejca.2008.09.025 1:CAS:528: DC%2BD1cXhsVKltr%2FI
27. DL Iden TM Allen 2001 In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach Biochim Biophys Acta 1513 207 216 11470092 10.1016/S0005-2736(01) 00357-1 1:CAS:528:DC%2BD3MXltFyqurY%3D (Pubitemid 32706418)
28. A Soundararajan A Bao WT Phillips R Perez III BA Goins 2009 [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model Nuc Med Biol 36 515 524 10.1016/j.nucmedbio.2009.02.004 1:CAS:528:DC%2BD1MXnt1Gqt78%3D
29. CR Miller B Bondurant SD McLean KA McGovern DF O'Brien 1998 Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes Biochemistry 37 12875 12883 9737866 10.1021/bi980096y 1:CAS:528:DyaK1cXlsVKmtb8%3D (Pubitemid 28433520)
30. Y Wang O Roche MS Yan, et al. 2009 Regulation of endocytosis via the oxygen-sensing pathway Nat Med 15 319 324 19252501 10.1038/nm.1922 1:CAS:528:DC%2BD1MXisVOrtLc%3D
31. BA Teicher 2009 Acute and chronic in vivo therapeutic resistance Biochem Pharmacol 77 1665 1673 19428320 10.1016/j.bcp.2009.01.006 1:CAS:528: DC%2BD1MXkvVSqtr4%3D
32. HP Yao YL Luo L Feng LF Cheng Y Lu W Li MH Wang 2006 Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase Cancer Biol Ther 5 1179 1186 16880737 10.4161/cbt.5.9.3073 1:CAS:528:DC%2BD2sXktleiug%3D%3D (Pubitemid 44772234)
33. JM Brown WR Wilson 2004 Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 437 447 15170446 10.1038/nrc1367 1:CAS:528:DC%2BD2cXksVaisbs%3D (Pubitemid 38745529)
34. LH Patterson SR McKeown 2000 AQ4 N: a new approach to hypoxia-activated cancer chemotherapy Br J Cancer 83 1589 1593 11104551 10.1054/bjoc.2000.1564 1:CAS:528:DC%2BD3MXktFClsg%3D%3D (Pubitemid 32001698)
35. T Shibata AJ Giaccia JM Brown 2002 Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy Neoplasia 4 40 48 11922390 10.1038/sj.neo.7900189 1:CAS:528:DC%2BD38Xht1Wltb4%3D (Pubitemid 34075889)
36. AV Patterson KJ Williams RL Cowen, et al. 2002 Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours Gene Ther 9 946 954 12085243 10.1038/sj.gt.3301702 1:CAS:528: DC%2BD38Xksl2mtr0%3D (Pubitemid 34812285)
37. GL Semenza 2003 Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 721 732 13130303 10.1038/nrc1187 1:CAS:528:DC%2BD3sXotFCiu70%3D (Pubitemid 37328811)
38. AD Ricart AW Tolcher 2007 Technology insight: cytotoxic drug immunoconjugates for cancer therapy Nat Clin Pract Oncol 4 245 255 17392715 10.1038/ncponc0774 1:CAS:528:DC%2BD2sXjs12rsbw%3D (Pubitemid 46510534)
39. C Mamot DC Drummond CO Noble V Kallab Z Guo K Hong DB Kirpotin JW Park 2005 Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res 65 11631 11638 16357174 10.1158/0008-5472.CAN-05-1093 1:CAS:528:DC%2BD2MXhtlWiu7rK (Pubitemid 41821723)
40. CR Patra R Bhattacharya E Wang, et al. 2008 Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent Cancer Res 68 1970 1978 18339879 10.1158/0008-5472.CAN-07-6102 1:CAS:528:DC%2BD1cXjtFOhtrg%3D (Pubitemid 351416584)
41. C Mamot DC Drummond U Greiser K Hong DB Kirpotin JD Marks JW Park 2003 Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Res 63 3154 3161 12810643 1:CAS:528:DC%2BD3sXks1eiur4%3D (Pubitemid 36735867)
42. K Cho X Wang S Nie ZG Chen DM Shin 2008 Therapeutic nanoparticles for drug delivery in cancer Clin Cancer Res 14 1310 1316 18316549 10.1158/1078-0432.CCR-07-1441 1:CAS:528:DC%2BD1cXislSrsr0%3D (Pubitemid 351413909)
43. P Carter 2001 Improving the efficacy of antibody-based cancer therapies Nat Rev Cancer 1 118 129 11905803 10.1038/35101072 1:CAS:528: DC%2BD38XlvF2qsLw%3D (Pubitemid 33741887)
44. A Thangasamy J Rogge S Ammanamanchi 2009 Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells J Biol Chem 284 14001 14010 19307182 10.1074/jbc.M809320200 1:CAS:528:DC%2BD1MXlvV2jt7Y%3D
45. AE Greijer MC de Jong GL Scheffer A Shvarts PJ van Diest E van der Wall 2005 Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells Cell Oncol 27 43 49 15750206 1:CAS:528:DC%2BD2MXhs1GhsbY%3D (Pubitemid 40387191)
46. KM Comerford TJ Wallace J Karhausen NA Louis MC Montalto SP Colgan 2002 Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene Cancer Res 62 3387 3394 12067980 1:CAS:528:DC%2BD38XkslWqsLc%3D (Pubitemid 34651384)
47. C Sauvant M Nowak C Wirth B Schneider A Riemann M Gekle O Thews 2008 Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38 Int J Cancer 123 2532 2542 18729196 10.1002/ijc.23818 1:CAS:528:DC%2BD1cXhtlyru7vJ